Latest / This Week In Medicine / 7 28 2025

Transcript

7 28 2025 · This Week In Medicine

• 0:00
  [SPEAKER_00]: Welcome to this week in medicine, your filtered medical journal summary.
• 0:03
  [SPEAKER_00]: Looking to stay up to date with the latest medical research but short on time?
• 0:07
  [SPEAKER_00]: This week in medicine has you covered.
• 0:09
  [SPEAKER_00]: Our AI-generated podcast provides you with a convenient, on the go solution to keep you informed about the most significant developments in the medicine field.
• 0:16
  [SPEAKER_00]: Each episode offers a filtered and concentrated summary of key journal articles, allowing you to stay informed without the need to sift through pages of research papers.
• 0:24
  [SPEAKER_00]: With this week in medicine, listening is faster than reading, and you can consume valuable medical knowledge while commuting, exercising, or during your daily routine.
• 0:32
  [SPEAKER_01]: Hi, this week in medicine, we will be discussing.
• 0:35
  [SPEAKER_01]: First we will be discussing articles in New England Journal of Medicine.
• 0:39
  [SPEAKER_01]: Weekly fixed dose insulin-epsitora in Type II diabetes without previous insulin therapy.
• 0:45
  [SPEAKER_01]: Background.
• 0:46
  [SPEAKER_01]: In previous treat to target trials, adjustments to the dose of basal insulin have been made at least weekly, according to fasting blood glucose levels.
• 0:55
  [SPEAKER_01]: A fixed dose regimen of insulin F-satura alpha, F-satura, a once-weekly basal insulin, may provide a benefit in adults with type II diabetes, who have not received previous insulin therapy conclusions.
• 1:08
  [SPEAKER_01]: In adults with type II diabetes, who had not previously received insulin, once-weekly F-satura, administered in a fixed dose regimen, was not inferior to once daily glycine in reducing glycated hemoglobin levels.
• 1:22
  [SPEAKER_01]: Next article.
• 1:23
  [SPEAKER_01]: Trust azumab deructicon or ramosuriumab plus pakletaxil in gastric cancer.
• 1:29
  [SPEAKER_01]: Background.
• 1:30
  [SPEAKER_01]: On the basis of phase two studies, trust azumab deructicon was approved for patients with human epidermal growth factor receptor two, her two positive metastatic gastric cancer, or gastrosophageal junction adenocarcinoma.
• 1:44
  [SPEAKER_01]: who had previously received Trastizumab-based therapy.
• 1:47
  [SPEAKER_01]: Ramusurumab-plus-pacletaxel is also a standard second-line treatment option regardless of her two-status conclusions.
• 1:55
  [SPEAKER_01]: Trastizumab-Dirux-Dicken led to significantly longer overall survival than Ramusurumab-plus-pacletaxel, among patients with her two-positive metastatic gastric cancer, or gastrosophageal junction at anocarsanoma.
• 2:09
  [SPEAKER_01]: Adversive ends were common in both groups.
• 2:12
  [SPEAKER_01]: Events of interstitial lung disease or pneumonitis with trastazumab deructicon, a known risk, were mainly low-grade.
• 2:19
  [SPEAKER_01]: Next article.
• 2:21
  [SPEAKER_01]: Tarlitumab and small cell lung cancer after platinum-based chemotherapy.
• 2:25
  [SPEAKER_01]: Background.
• 2:27
  [SPEAKER_01]: Tarlitumab, a bispecific delta like ligand-three directed T cell and gager immunotherapy, received accelerated approval for the treatment of patients with previously treated small cell lung cancer.
• 2:39
  [SPEAKER_01]: Whether Talitumab is more effective than chemotherapy in the treatment of patients whose small cell lung cancer has progressed during or after initial platinum-based chemotherapy is not known.
• 2:49
  [SPEAKER_01]: Conclusions.
• 2:51
  [SPEAKER_01]: Treatment with Talitumab led to longer overall survival than chemotherapy among patients with small cell lung cancer.
• 2:58
  [SPEAKER_01]: whose disease had progressed during or after platinum-based chemotherapy.
• 3:03
  [SPEAKER_01]: Next article, I've remacked into control malaria, a cluster randomized trial.
• 3:09
  [SPEAKER_01]: Background.
• 3:10
  [SPEAKER_01]: Malaria control and elimination is threatened by the spread of insecticide resistance and behavioral adaptation of vectors.
• 3:17
  [SPEAKER_01]: Whether mass administration of Ivermectin, a broad spectrum anti-paracitic drug that also kills mosquitoes feeding untreated persons, can reduce malaria transmission is unclear conclusions.
• 3:29
  [SPEAKER_01]: Among children five to fifteen years of age who were living in an area with high coverage and use of bed nets, Ivermectin, administered once a month for three consecutive months, resulted in a twenty-six percent lower incidence of malaria infection than al bendazole, no safety concerns were identified.
• 3:52
  [SPEAKER_01]: Next we will be discussing articles from Journal of American Medical Association.
• 3:57
  [SPEAKER_01]: Tell a health and online cognitive behavioral therapy for chronic pain.
• 4:01
  [SPEAKER_01]: Question.
• 4:02
  [SPEAKER_01]: How effective are remote, scalable cognitive behavioral therapy skills training programs for chronic pain, CBTCP?
• 4:10
  [SPEAKER_01]: for individuals with high-impact chronic pain findings.
• 4:14
  [SPEAKER_01]: In this randomized clinical trial that included two thousand three hundred thirty-one participants, both the telephonic slash video health coach led, and the online self-completed CBTCP programs resulted in a significantly greater proportion of participants achieving at least thirty percent improvement from baseline in pain severity at three months, compared with usual care.
• 4:35
  [SPEAKER_01]: Intervention benefits were sustained at twelve months.
• 4:38
  [SPEAKER_01]: And the three month outcome was better for those in the health coach group versus the online self-completed program, meaning these remote scalable CBTCP programs are effective for treating individuals with high-impact chronic pain.
• 4:57
  [SPEAKER_01]: Next we will be discussing articles from Annals of Internal Medicine Glucogon-like peptide-one receptor, agonis and incidence of dementia among older adults with type II diabetes.
• 5:07
  [SPEAKER_01]: Background Glucogon-like peptide-one receptor agonis, GLP-one Ross, have been shown to decrease blood glucose levels, promote weight loss, and prevent cardiovascular events.
• 5:19
  [SPEAKER_01]: However, evidence is limited regarding their effect on dementia.
• 5:23
  [SPEAKER_01]: Although emerging observational studies, some with serious methodological limitations have suggested large reductions in dementia associated with GLP-one RAS that may not be entirely causally related, conclusion.
• 5:37
  [SPEAKER_01]: Among older adults with diabetes, no clear evidence was found that the incidence of dementia differed overall between patients using GLP-one-rass versus DPP-IVs.
• 5:47
  [SPEAKER_01]: Under conventional statistical criteria, an effective GLP-one-rass between a thirty-nine percent decrease, and a five percent increase in risk for dementia, was highly compatible with the data, although estimates differed by age.
• 6:01
  [SPEAKER_01]: Randomized trials are needed to quantify the effect of GLP-one-rass on dementia.
• 6:12
  [SPEAKER_01]: Next we will be discussing articles from British Medical Journal.
• 6:16
  [SPEAKER_01]: Global, regional, and national characteristics of the main causes of increased disease burden due to the COVID-nineteen pandemic.
• 6:24
  [SPEAKER_01]: Objective.
• 6:25
  [SPEAKER_01]: To quantify and identify the main causes of increased disease burden due to coronavirus disease, COVID-nineteen, pandemic conclusion.
• 6:35
  [SPEAKER_01]: The COVID-nineteen pandemic significantly increased the burden of several non-COVID conditions, particularly mental health disorders, malaria and young children in the African region, and stroke and ischemic heart disease in older adults, with notable disparities across age and sex.
• 6:51
  [SPEAKER_01]: These findings underscore the urgent need to strengthen health system resilience, enhance integrated surveillance, and adopt syndemic informed strategies to support equitable preparedness for future public health emergencies.
• 7:10
  [SPEAKER_01]: Next we will be discussing articles from Lancet Global Regional and National Trends in routine childhood vaccination coverage from nineteen eighty to twenty twenty three with forecast to twenty thirty a systematic analysis for the global burden of disease study twenty twenty three background since its inception in nineteen seventy four
• 7:30
  [SPEAKER_01]: The essential program on immunization, EPI, has achieved remarkable success, averting the deaths of an estimated one hundred fifty four million children worldwide through routine childhood vaccination.
• 7:42
  [SPEAKER_01]: However, more recent decades have seen persistent coverage in equities and stagnating progress, which have been further amplified by the COVID-nineteen pandemic.
• 7:52
  [SPEAKER_01]: In twenty-nineteen, WHO said ambitious goals for improving vaccine coverage globally through the immunization agenda twenty-thirty, i.e.
• 8:00
  [SPEAKER_01]: twenty-thirty.
• 8:01
  [SPEAKER_01]: Now halfway through the decade, understanding past and recent coverage trends can help inform and reorient strategies for approaching these aims in the next five years.
• 8:10
  [SPEAKER_01]: Interpretation.
• 8:12
  [SPEAKER_01]: Our estimates of current vaccine coverage and forecast to twenty-thirty suggest that achieving IA-twenty-thirty targets, such as having zero dose children, compared with twenty-nineteen levels, and reaching ninety percent global coverage for life course vaccines, DTP-three, PCV-three, and MCV-two, will require accelerated progress.
• 8:32
  [SPEAKER_01]: Substantial increases in coverage are necessary in many countries and territories, with those in Sub-Saharan Africa and South Asia facing the greatest challenges.
• 8:41
  [SPEAKER_01]: Recent declines will need to be reversed to restore previous coverage levels in Latin America and the Caribbean, especially for DTP-One, DTP-Three, and Paul-Three.
• 8:51
  [SPEAKER_01]: These findings underscore the crucial need for targeted equitable immunization strategies.
• 8:56
  [SPEAKER_01]: Strengthening primary health care systems, addressing vaccine misinformation and hesitancy, and adapting to local contexts, are essential to advancing coverage.
• 9:06
  [SPEAKER_01]: COVID-nineteen pandemic recovery efforts.
• 9:09
  [SPEAKER_01]: such as WHO's Big Catchup, as well as efforts to bolster routine services, must prioritize reaching marginalized populations and target subnational geographies to regain lost ground and achieve global immunization goal.
• 9:29
  [SPEAKER_01]: Next we will be discussing articles in the field of hematoconcology.
• 9:33
  [SPEAKER_01]: Here are the articles from JAMA oncology.
• 9:35
  [SPEAKER_01]: Navalumab and Ipalumab combination treatment in advanced ovarian and endometrial clear cell cancer set non-randomized clinical trial.
• 9:44
  [SPEAKER_01]: Question, what is the efficacy of Navalumab and Ipalumab combination treatment in patients with advanced gynecological clear cell cancers?
• 9:53
  [SPEAKER_01]: Findings.
• 9:54
  [SPEAKER_01]: In this non-randomized clinical trial, including twenty-eight patients with gynecological clear cell cancers, an objective response rate of fifty-four percent, and a six-month progression-free survival of fifty-eight percent was observed, with all responses being ongoing.
• 10:09
  [SPEAKER_01]: Meaning Nevolumab and Epilymumab combination therapy has significant activity in gynecological clear cell cancers and warrants further investigation.
• 10:24
  [SPEAKER_01]: Next we will be discussing articles in the field of gastroenterology.
• 10:28
  [SPEAKER_01]: Here are the articles from Journal of Hepatology, All Cause and Cos-specific mortality and patients with chronic hepatitis B and concurrent stitotic liver disease, cumulative metabolic burden dose, dependently increases mortality risks and patients with CHB and concurrent SLD.
• 10:45
  [SPEAKER_01]: New onset diabetes, malitis, hypertension, and weight gain further exacerbate the risks of mortality.
• 10:52
  [SPEAKER_01]: Patients with concurrent SLD have a lower risk of mortality than those without SLD, regardless of metabolic dysfunction.
• 11:00
  [SPEAKER_01]: Routine screening and the aggressive identification of metabolic dysfunction are crucial.
• 11:11
  [SPEAKER_01]: Here are the articles from gastroenterology.
• 11:13
  [SPEAKER_01]: capsule andoscopy guided proactive treat to target versus continued standard care in patients with quiescent Crohn's disease, a randomized controlled trial.
• 11:23
  [SPEAKER_01]: Background and aims.
• 11:25
  [SPEAKER_01]: Optimal treat to target strategies for Crohn's disease, CD, are still being sought.
• 11:30
  [SPEAKER_01]: The value of video capsule andoscopy, VCE, to guide proactive treat to target optimization and CD was examined conclusions.
• 11:39
  [SPEAKER_01]: A VCE guided treat to target strategy for patients with CD and remission confers superior clinical outcomes compared with continued standard care.
• 11:54
  [SPEAKER_01]: Here are the articles from clinical gastroenterology.
• 11:57
  [SPEAKER_01]: Real-world clinical effectiveness and safety of fetalismab and Adelima Mab in biologic knife patients with Crohn's disease, results from the evolved study.
• 12:07
  [SPEAKER_01]: Goals.
• 12:08
  [SPEAKER_01]: This study evaluated the real-world effectiveness and safety of fetalismab versus Adelima Mab.
• 12:14
  [SPEAKER_01]: Over twelve months of treatment in biologic naïve patients with Crohn's disease, CD, using data from the Evolve study.
• 12:22
  [SPEAKER_01]: A comparison of Vidalism app and Adelima Map may help to better position them in the therapeutic algorithm for moderate to severe CD sec conclusions.
• 12:31
  [SPEAKER_01]: In a real-world setting, biologic naïve patients with CD treated with fidolismab demonstrated a greater likelihood of drug persistence and achieving clinical remission with equivalent rates of response and mucosal healing versus edalimumab treated patients.
• 12:53
  [SPEAKER_01]: Next we will be discussing articles in the field of cardiology.
• 12:57
  [SPEAKER_01]: Here are the articles from circulation.
• 12:59
  [SPEAKER_01]: efficacy and safety of inclyceron in adolescents with genetically confirmed homozygous familial hypercolycerolemia results from the double blind placebo controlled part of the Orion-Thirteen randomized trial.
• 13:12
  [SPEAKER_01]: Background
• 13:14
  [SPEAKER_01]: Amazagus familial hyper cholesterolemia, HoFH, is a genetic disease characterized by high levels of low-density lipoprotein cholesterol, LDLC, present from birth, leading to early onset and progressive atherosclerotic cardiovascular disease.
• 13:31
  [SPEAKER_01]: Early treatment initiation is crucial for cardiovascular risk reduction.
• 13:35
  [SPEAKER_01]: However, many patients do not reach LDLC treatment goals.
• 13:39
  [SPEAKER_01]: Inclusive.
• 13:40
  [SPEAKER_01]: A small interfering RNA targeting hepatic PCSK-nine.
• 13:44
  [SPEAKER_01]: Proprotein-converteous-sutalycin-slash-cushin-type-nine.
• 13:48
  [SPEAKER_01]: Is effective and well-tolerated in adult patients with hyperlepidemia.
• 13:52
  [SPEAKER_01]: However, it has not yet been studied in pediatric patients.
• 13:56
  [SPEAKER_01]: See you on Clusions.
• 13:57
  [SPEAKER_01]: In a one-year randomized controlled study, Part I of Orion XIII, in Cliceron was effective in lowering LDLC in adolescents with HoFH and was well tolerated.
• 14:08
  [SPEAKER_01]: These results support in Cliceron as a potentially useful addition for the treatment of adolescents with HoFH and a minimum of LDLR residual activity.
• 14:23
  [SPEAKER_01]: Here are the articles from journals of the American College of Cardiology.
• 14:27
  [SPEAKER_01]: Bialamus Alluding Biomatric Stent versus a dual therapy cyberlimus alluding stent in PCI, the sort out eleven randomized trial.
• 14:36
  [SPEAKER_01]: Background.
• 14:38
  [SPEAKER_01]: Percutaneous coronary intervention.
• 14:40
  [SPEAKER_01]: PCI, with new generation drug eluding stints, DES, is still associated with risk of target lesion failure TLF.
• 14:49
  [SPEAKER_01]: The Bialamus A-Nine eluding biometrics alpha stint, BES, with biodegradable polymer and thin struts, has not been compared head to head with another contemporary DES conclusions.
• 15:01
  [SPEAKER_01]: Bess was not inferior to DTS at one year follow-up regarding the primary endpoint of TLF.
• 15:07
  [SPEAKER_01]: However, Bess was associated with significantly increased risk of definite stent thrombosis.
• 15:19
  [SPEAKER_01]: from jamacardiology.
• 15:21
  [SPEAKER_01]: OCT versus angiography for guidance of percutaneous coronary intervention of calcified lesions, the colipso-randomized clinical trial.
• 15:30
  [SPEAKER_01]: Question is optical coherence tomography, OCT, imaging superior to angiography when guiding percutaneous coronary intervention, PCI.
• 15:41
  [SPEAKER_01]: Procedures in calcified coronary lesions?
• 15:43
  [SPEAKER_01]: Findings.
• 15:44
  [SPEAKER_01]: In this randomized clinical trial, an OCT-based strategy, including lesion analysis and standardized plaque preparation according to predefined algorithms, resulted in better stent implantation results, stent expansion and opposition than angiography guidance, without any additional safety concern.
• 16:02
  [SPEAKER_01]: Meaning considering the high incidence of calcified stenuses among patients with stable coronary artery disease,
• 16:09
  [SPEAKER_01]: and the poorer prognosis of PCI in this situation.
• 16:12
  [SPEAKER_01]: Use of this OCT-based strategy could improve the clinical outcome of these patients by improving the quality of stent implantation.
• 16:25
  [SPEAKER_01]: Next we will be discussing articles in the field of endocrinology.
• 16:29
  [SPEAKER_01]: Here are the articles from Journal of Clinical Endocrinology and Metabolism.
• 16:34
  [SPEAKER_01]: The role of whole food plant-based food intake on post-prandyoglasemia in type one diabetes.
• 16:40
  [SPEAKER_01]: Context.
• 16:41
  [SPEAKER_01]: A whole-food plant-based diet.
• 16:44
  [SPEAKER_01]: WFPBD, minimally processed foods with limited consumption of animal products, is associated with improved health outcomes.
• 16:51
  [SPEAKER_01]: The benefits of WFPBD are under-explored in individuals with type one diabetes, T-one D, objective.
• 17:00
  [SPEAKER_01]: The primary objective of this analysis is to evaluate the association between WFPBD on Glacemia in individuals with T-One D. Conclusion.
• 17:30
  [SPEAKER_01]: you
• 17:36
  [SPEAKER_01]: Here are the articles from diabetes care.
• 17:38
  [SPEAKER_01]: Associations of concurrent hypertension and type II diabetes with mortality outcomes, a prospective study of U.S.
• 17:46
  [SPEAKER_01]: adults.
• 17:47
  [SPEAKER_01]: Objective.
• 17:48
  [SPEAKER_01]: To investigate associations of concurrent hypertension and type II diabetes, T-II D, with mortality in U.S.
• 17:55
  [SPEAKER_01]: adults, and elucidate differences by sex, race, and ethnicity-time inclusions.
• 18:01
  [SPEAKER_01]: Concurrent hypertension and T-IID predict high mortality risk, underscoring the critical need for contextual interventions that extend health span in the U.S.
• 18:15
  [SPEAKER_01]: Next, we will be discussing articles in the field of pulmonary and critical care.
• 18:20
  [SPEAKER_01]: Here are the articles from Chest.
• 18:22
  [SPEAKER_01]: Clinical remission over two years with Ben Ralazumaab in severe eocinophilic asthma.
• 18:28
  [SPEAKER_01]: Background.
• 18:29
  [SPEAKER_01]: Long-term real-world data on clinical remission and patients with severe eocinophilic asthma, SEA, receiving biologics are lacking.
• 18:37
  [SPEAKER_01]: We describe clinical remission over two years in patients with C receiving binerala zoomab research question.
• 18:44
  [SPEAKER_01]: Is long-term clinical remission a viable goal for patients with C receiving binerala zoomab interpretation?
• 18:51
  [SPEAKER_01]: Our results indicate that clinical remission is a realistic goal.
• 18:55
  [SPEAKER_01]: Sustainable up to two years and around one-third of patients with C receiving binerala zoomab.
• 19:00
  [SPEAKER_01]: In this study, remission was more likely in patients with lower baseline disease burden.
• 19:05
  [SPEAKER_01]: suggesting that further research is warranted regarding whether earlier initiation of a biologic may be beneficial.
• 19:17
  [SPEAKER_01]: Here are the articles from the American Journal of Respiratory and Critical Care Medicine.
• 19:21
  [SPEAKER_01]: Deep learning estimation of small airway disease from inspired story chest computed tomography, clinical validation, repeatability, and associations with adverse clinical outcomes in chronic obstructive pulmonary disease.
• 19:35
  [SPEAKER_01]: Rational Quantifying Functional Small Airway Disease, FCID, requires additional expiratory computed tomography, CT, scans, limiting clinical applicability.
• 19:47
  [SPEAKER_01]: Artificial intelligence AI could enable FCID quantification from chest CT scans at total lung capacity, TLC.
• 19:55
  [SPEAKER_01]: Alone, FCADC.
• 19:57
  [SPEAKER_01]: Objectives.
• 19:58
  [SPEAKER_01]: To evaluate an AI model for estimating FCDTT, compare it with dual-volume parametric response mapping, FCIT, FCDPream, and assess its clinical associations and repeatability in chronic obstructive pulmonary disease, COPD.
• 20:14
  [SPEAKER_01]: Conclusions.
• 20:16
  [SPEAKER_01]: Small airway disease can be reliably assessed from a single inspiratory CT scan using generative AI, eliminating the need for an additional expiratory CT scan.
• 20:26
  [SPEAKER_01]: FCID estimation from Inspiratory CT correlates strongly with FCID pre-M, demonstrates a significant association with F-One decline, and offers greater repeatability.
• 20:43
  [SPEAKER_01]: Next we will be discussing articles in the field of nephrology.
• 20:47
  [SPEAKER_01]: Here are the articles from Clinical Journal of American Society of Nephrology.
• 20:51
  [SPEAKER_01]: Unveiling the causal relationship between thyroid and kidney function, a multivariable Mendelian randomization.
• 20:58
  [SPEAKER_01]: Key points.
• 21:00
  [SPEAKER_01]: Thyroid stimulating hormone levels were inversely associated with EGFRI, and hypocyroidism was correlated with lower EGFRI levels.
• 21:09
  [SPEAKER_01]: Multivariable Mandelian randomization analysis confirms a causal link between elevated thyroid stimulating hormone levels, and reduced eggifi in diverse populations.
• 21:19
  [SPEAKER_01]: Findings highlight the importance of considering thyroid dysfunction and CKD management and targeted treatments.
• 21:31
  [SPEAKER_01]: Here are the articles from kidney international reports.
• 21:35
  [SPEAKER_01]: Characterization of monogenic kidney disease and older patients with CKD.
• 21:40
  [SPEAKER_01]: Introduction Although ten percent of adults with chronic kidney disease, CKD have a monogenic cause, the characteristics of monogenic CKD in older adults, aged greater than or equal to sixty years, are less characterized.
• 21:55
  [SPEAKER_01]: We aimed to assess the clinical and genetic spectrum of older adults with CKD.
• 22:00
  [SPEAKER_01]: and the clinical utility of genetic findings conclusion.
• 22:04
  [SPEAKER_01]: In older patients with CKD, genetic testing revealed enriched variants associated with less penetrant phenotypes, often with the family history of CKD, which affects clinical management.
• 22:15
  [SPEAKER_00]: Thank you for listening to this week in medicine, your filtered medical journal summary.
• 22:20
  [SPEAKER_00]: Have a great week ahead, stay blessed and be humane.